GlaxoSmithKline (GSK) and Pfizer filed a stipulation to dismiss with prejudice GSK’s litigation in the United States District ...

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizers RSV vaccine, ...

Australian medicines regulator, the Therapeutic Goods Administration (TGA), has granted approval for mRESVIA (mRNA-1345), an ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely ...

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods ...

More top vaccine regulators at the FDA have either left or been forced out, which could hobble the agency's ability to ...

About mRESVIA (Respiratory Syncytial Virus Vaccine) mRNA-1345 is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein. The F glycoprotein is expressed on ...